Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.

* Context.--Programmed death ligand-1 (PD-L1) expression by tumors may enable them to avoid immunosurveillance. Objective.--To develop a PD-L1 immunohistochemical assay using the 22C3 anti-PD-L1 murine monoclonal antibody on the Dako platform as a possible companion diagnostic for pembrolizumab in p...

Descripción completa

Detalles Bibliográficos
Publicado en:Archives of Pathology & Laboratory Medicine Vol. 140; no. 11; pp. 1243 - 1250
Autores principales: Dolled-Filhart, Marisa, Roach, Charlotte, Toland, Grant, Stanforth, Dave, Jansson, Malinka, Lubiniecki, Gregory M., Ponto, Gary, Emancipator, Kenneth
Formato: pictorial research tables/charts Journal Article
Publicado: College of American Pathologists Nov2016
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=119227540&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 119227540
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00039985
        1FS
      jtl: Archives of Pathology & Laboratory Medicine
      issn: 00039985
      maglogo: N
    pubinfo:
      dt: Nov2016
      vid: 140
      iid: 11
      pid: 2550
      pub: College of American Pathologists
      place: Northfield, Illinois
    artinfo:
      ui:
        119227540
        119227540
        119227540
        10.5858/arpa.2015-0542-OA
        119227540
      ppf: 1243
      ppct: 7
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.
      aug:
        au:
          Dolled-Filhart, Marisa
          Roach, Charlotte
          Toland, Grant
          Stanforth, Dave
          Jansson, Malinka
          Lubiniecki, Gregory M.
          Ponto, Gary
          Emancipator, Kenneth
        affil: Department of Molecular Biomarkers and Diagnostics, Merck & Co, Inc, Kenilworth, New Jersey
      sug:
        subj:
          Carcinoma, Non-Small-Cell Lung Drug Therapy
          Antibodies, Monoclonal Therapeutic Use
          Carcinoma, Non-Small-Cell Lung Immunology
          Immunohistochemistry Methods
          Receptors, Immunologic Drug Effects
          Patient Selection Methods
          Clinical Assessment Tools
          False Negative Results
          False Positive Results
          Carcinoma, Non-Small-Cell Lung Mortality
          Decision Making, Clinical
          In Vivo Studies
          Prospective Studies
          Predictive Value of Tests
          Evaluation Research
          ROC Curve
          Kaplan-Meier Estimator
          Human
      ab: * Context.--Programmed death ligand-1 (PD-L1) expression by tumors may enable them to avoid immunosurveillance. Objective.--To develop a PD-L1 immunohistochemical assay using the 22C3 anti-PD-L1 murine monoclonal antibody on the Dako platform as a possible companion diagnostic for pembrolizumab in patients with non-small cell lung cancer. Design.--Tumor samples from 146 patients with non-small cell lung cancer treated with pembrolizumab in KEYNOTE-001 and for whom response data were available were scored according to their staining intensity by a single pathologist using 4 methods: percentage of tumor cells staining at any intensity (PS1), moderate/strong intensity (PS2), strong intensity (PS3), and H-score (PS1 + PS2 + PS3). The cutoff score for predicting response to pembrolizumab was determined using receiver operating characteristic analysis. Progression-free and overall survival were assessed in patients with measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (n = 146). Results.--The 4 scoring methods assessed performed similarly; PS1 with a 50% cutoff score is the simplest and easiest method to implement in practice. Response to pembrolizumab was observed in 19 of 44 patients (43%) with a PS1 score of 50% or higher and 8 of 102 patients (8%) with PS1 lower than 50% (odds ratio, 8.93). Median progression-free and overall survival was 4.0 months and not yet reached, respectively, for patients with a PS1 of 50% or higher, and 2.1 and 6.1 months, respectively, for those with PS1 lower than 50%. Conclusion.--The PD-L1 immunohistochemical assay shows the potential for enrichment of trial populations and as a companion diagnostic tool in non-small cell lung cancer.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N